incorporating the validated CpGs and Gleason sum was used to define and lock a final model to stratify men with metastatic-lethal versus non-recurrent PCa in a training dataset. Coefficients from the final model were then used to construct a DNA methylation score, which was evaluated by logistic regression and Receiver Operating Characteristic (ROC) curve analyses in an independent testing dataset.
Results: Five CpGs were technically validated and all were retained (P < 0.05) in the final model. The 5-CpG and Gleason sum coefficients were used to calculate a methylation score, which was higher in men with metastatic-lethal progression (P = 6.8 × 10 −6 ) in the testing dataset. For each unit increase in the score there was a four-fold increase in risk of metastatic-lethal events (odds ratio, OR = 4.0, 95%CI = 1.8-14.3). At 95% specificity, sensitivity was 74% for the score compared to 53% for Gleason sum alone. The score demonstrated better prediction performance (AUC = 0.91; pAUC = 0.037) compared to Gleason sum alone (AUC = 0.87; pAUC = 0.025).
Conclusions:
The DNA methylation score improved upon Gleason sum for predicting metastatic-lethal progression and holds promise for risk stratification of men with aggressive tumors. This prognostic score warrants further evaluation as a tool for improving patient outcomes.
K E Y W O R D S
biomarker validation, DNA methylation score, metastatic-lethal, prognostic, prostate cancer 1 | BACKGROUND Prostate cancer (PCa) is responsible for more than 26 000 deaths each year, and men initially diagnosed with clinically localized disease comprise a substantial proportion of this mortality. 1 Recent estimates indicate that over 80% of patients have tumors confined to the prostate at first presentation, [2] [3] [4] and of those treated with radical prostatectomy many will have a durable cure. 5, 6 However, a subset of surgically treated patients will develop biochemical recurrence and some will progress to metastatic, life-threatening PCa. 6, 7 Genomic biomarkers with prognostic value for stratifying patients at high risk for metastatic progression and diseasespecific mortality are needed to advance personalized medicine. 8, 9 Molecular studies of tumor tissue have led to development of commercial tests based on gene expression scores for prediction of metastasis or PCa death after prostatectomy, with AUC values ranging from 0.75 to 0.82 for these mRNA-based assays. [8] [9] [10] [11] However, rigorous comparative effectiveness studies of these assays and prospective clinical studies are needed to confirm the performance characteristics of these tests. In addition, there are other fluid-based 12 and tumor tissuebased 13, 14 biomarker panels that may aid risk stratification of men diagnosed with localized disease, but these also require further evaluation.
Alterations in DNA methylation may occur early in tumorigenesis, are the most recurrent events in metastatic PCa, and can impact gene expression. 15, 16 We hypothesize that the DNA methylation profile of a primary prostate tumor may reveal its aggressiveness potential, and because the stability of tumor DNA exceeds that of RNA, DNA-based biomarkers may prove to be more reliable. Indeed, a recent study found that the performance characteristics of DNA methylation-based biomarkers were superior to expression-based ones for detecting cancer in prostate biopsy tissue. 17 We previously used primary tumor tissue-derived DNA samples to develop a panel of eight differentially methylated CpGs that improved upon Gleason sum for classifying post-prostatectomy patients who experienced metastatic-lethal progression as compared to their counterparts who remained recurrence-free for at least 5 years following surgery.
The panel of eight CpG sites was initially identified using epigenome-wide data from a training cohort and was validated in an independent dataset, with AUC values for individual CpGs in combination with Gleason sum ranging from 0.82 to 0.89 for prediction of metastatic-lethal outcomes. 13 To further investigate the potential clinical utility of these DNA methylation biomarkers, we first performed pyrosequencing for technical validation of each CpG, created a methylation score based on Gleason sum and the CpGs that were technically validated and were retained in the final locked model, and then evaluated the score's performance in an independent testing dataset. School-based nested case-control dataset. These populations were described previously. 13 Briefly, the FH cohort includes was used to measure epigenome-wide methylation using beads with target-specific probes designed to interrogate individual CpG sites (>485 000). 20 All samples from the FH and EV patients were assayed using the HM450 array as previously described. 13 The UM samples were assayed in a single batch using the HM450 array. PCa outcome events were randomly distributed across the plate, laboratory personnel were blinded to clinical information and the location of samples, and the same laboratory technician performed all the methylation assays.
Failed samples were identified by using the detection P-value metric (probability of a CpG being detected above the background level defined by negative control probes) according to Illumina protocols. A sample was excluded if less than 95% of the CpG sites for that sample on the HM450 array were detected with a detection P-value <0.05. The final number of patients in the training dataset was 392 (344 non-recurrent, 48 metastatic-lethal) and in the testing dataset was 34 (11 non-recurrent, 23 metastatic-lethal). Further, CpG sites with a detection P-value of >0.01 were excluded. After data filtering, 477 460 CpGs were available in each of the FH, EV, and UM datasets.
| Pyrosequencing technical validation
The panel of eight differentially methylated CpGs previously shown to have prognostic value based on HM450 array data 13 Table SI ).
The PCR amplification step was performed using the Qiagen PyroMark (0, 20, 40, 60, 80, and 100%) were used as "calibrators" to correct PCR bias by means of cubic polynomial regression before assessing the clinical samples. 21 Pyrosequencing values of <0 or >100 were replaced with 0 or 100, respectively. The pyrosequencing assays were run using the matched (ie, the same) tumor DNA aliquots used for the HM450 array in order to assess the accuracy of the array results at each CpG site and to establish pyrosequencing assays for this panel of CpGs that could be used for future clinical testing of these biomarkers.
| Statistical analysis
The HM450 array data for the UM patients were processed using the minfi package in R as previously described for the FH and EV datasets. 13 Briefly, the data were normalized using subset-quantile within array normalization (SWAN). 
| RESULTS
Recent epigenome-wide tumor DNA methylation profiling by our group uncovered eight differentially methylated CpGs that classified radical prostatectomy patients who experienced metastatic-lethal progression as compared to those who remained recurrence-free for more than 5 years post-surgery. 13 Five of these eight candidate CpGs were technically validated based on their strong correlation (r > 0.70) with HM450 data using an orthogonal pyrosequencing-based assay ( Figure S1) .
Selected clinical characteristics of the combined FH and EV dataset (training) and the UM dataset (testing) are shown in Table 2 . In both datasets, men with no evidence of recurrence were similar in age at diagnosis to those who developed metastasis or died of PCa. As expected, men who experienced metastatic progression had higher
Gleason sum tumors, a higher frequency of regional stage disease based on surgical pathology, and higher diagnostic PSA levels.
After quality control and data filtering using the same procedures as for the FH and EV datasets, DNA methylation data were available for 23 men who developed metastatic-lethal PCa and 11 who remained disease-free in the UM dataset. The 24 drop-outs (11 non-recurrent, 6 metastatic-lethal) were primarily due to low input DNA as macrodissection of tumor tissue from five slides for these patients did not yield sufficient tumor DNA for the HM450 array. and PSA level at diagnosis were not significantly different in either the metastatic-lethal or the non-recurrent PCa group when comparing those with versus without available methylation data (all P > 0.10).
Forward model selection resulted in all five technically validated CpG biomarkers being retained in the final locked model with Gleason sum (all P < 0.05). Study site was included in the model to account for the different study designs (FH, cohort; EV, nested case-control), but the coefficients for Gleason sum and the five CpGs were similar when study site was excluded from the model. Table 3 shows the genetic and epigenetic locations of these five differentially methylated CpGs. One of the CpGs (in the PI15 gene) was hypermethylated in metastatic-lethal versus nonrecurrent patients whereas the other four CpGs had lower methylation levels in patients with metastatic-lethal progression. Two of the CpGs, one each in the PI15 and the FHAD1 gene, are in the promoter region.
The β-coefficients for five CpGs and Gleason sum from the locked model (Table 3) were then applied to the UM patients to calculate a DNA methylation score, which ranged from −3.01 to 3.70 (median −0.04) in the testing dataset ( Figure 1 ). The mean methylation score differed significantly between metastatic-lethal compared to recurrence-free patients (mean difference = 2.49, P = 6.8 × 10 the addition of PSA, stage, and year of diagnosis did not substantially improve either prediction model. This represents a 4.6% higher probability of correctly classifying men at high risk for metastatic-lethal progression, although the difference in the AUCs was not statistically significant (P = 0.33). However, the 48% increase in the pAUC for the score relative to Gleason sum alone (0.037 vs 0.025, respectively) was a significant improvement (P = 0.01). At a fixed 95% specificity, sensitivity increased by 0.21 (from 53% to 74%) when adding the methylation score. This represents a 39.6% higher probability of correctly classifying patients at high risk for developing metastaticlethal events, while minimizing the probability of misclassifying lowrisk men. This result agrees with our a priori decision to evaluate the methylation score at high specificity because of our translational goal of developing a biomarker test with a low false-positive fraction (<5%).
| DISCUSSION
Recently, we identified a panel of eight differentially methylated CpGs in primary PCa that stratified patients surgically treated for localized disease who subsequently developed metastatic progression or died of their cancer from similar patients who remained recurrence-free for at least 5 years following radical prostatectomy. 13 Building upon those findings, here we report results from technical validation of these biomarkers by pyrosequencing assays. In addition, a DNA methylation score based on five technically validated CpGs and Gleason sum was developed and tested for its ability to predict deleterious outcomes in an independent dataset. Each unit increase in the score was associated with a significant four-fold increase in the risk of metastatic-lethal events. In an independent testing dataset, the methylation score had a better performance profile (AUC = 91%; pAUC = 0.037) than Gleason sum alone (AUC = 87%; pAUC = 0.025). Furthermore, at a fixed specificity of 95% the methylation score had a higher sensitivity compared to Gleason sum alone, 74% versus 53%, respectively.
The primary goal of this research is to improve identification of biologically aggressive prostate tumors, which have acquired a particular DNA methylation signature correlated with subsequent metastasis and lethality. Because adjuvant therapy and selection to clinical trials may be recommended for the subset of men classified as high-risk by the methylation score, our analytical strategy was to find candidate biomarkers with a high specificity, that is, a low false-positive rate. 13 This approach should provide more confidence that a positive test result will in fact target early adjuvant therapy and more intense surveillance to patients at truly high risk for developing metastasis, avoiding overtreatment, and adverse effects of adjuvant therapies in men with low-risk tumors.
Localized PCa treated with radical prostatectomy has a spectrum of cancer-related outcomes, from lasting cure to biochemical recurrence, metastatic progression, and disease-specific mortality. Molecular biomarkers to identify tumors with high metastatic potential soon after outcomes. Another strength of the study is its use of independent training and testing datasets to define, create, and then test the methylation score, which avoids over-fitting of the data. Lastly, as discussed in our earlier paper, 13 there is biological plausibility for the genes encompassing the CpG sites included in the DNA methylation score contributing to tumor aggressiveness.
There are also several limitations of our study, including the small sample size of the testing dataset. This was further reduced due to The score increased sensitivity by 0.21 (from 53% for Gleason sum alone to 74% for the score) at 95% specificity, representing a 39.6% improvement in identification of truly high-risk men who may benefit from adjuvant therapy and more intense surveillance for metastatic progression following radical prostatectomy. In terms of clinical translation, at 100% specificity the DNA methylation score was able to identify six additional high-risk patients (ie, 26% of the 23 patients) with metastatic-lethal events in the testing dataset who would have been missed based on the use of Gleason sum alone or
Gleason sum, diagnostic PSA and pathologic stage combined for risk stratification. This indicates that with high specificity (<5% falsepositives) the methylation score could markedly improve the selection of patients at high risk for metastatic-lethal progression, which is particularly relevant for those patients (over 25% in the testing dataset) who may be misclassified as low risk and forego potentially life-saving adjuvant treatment. Given these promising results, this prognostic tumor DNA methylation score warrants further evaluation for its clinical utility and ability to improve PCa patient outcomes.
